CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Market Closed 01-23 16:00:00 EST

7.27

-0.17

-2.28%

盘后7.28

+0.01+0.14%

19:10 EST

High7.52	Low7.15	Vol2.52M
Open7.36	D1 Closing7.44	Amplitude5.04%
Mkt Cap572.80M	Tradable Cap535.76M	Total Shares78.79M
T/O18.50M	T/O Rate3.41%	Tradable Shares73.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":7.27,"timestamp":1769202000000,"preClose":7.44,"halted":0,"volume":2515169,"hourTrading":{"tag":"盘后","latestPrice":7.28,"preClose":7.27,"latestTime":"19:10 EST","volume":40257,"amount":292698.8893,"timestamp":1769213432636,"change":0.01,"changeRate":0.001376,"amplitude":0.008102},"delay":0,"changeRate":-0.022849462365591506,"floatShares":73694900,"shares":78789045,"eps":2.0624602,"marketStatus":"Market Closed","change":-0.17,"latestTime":"01-23 16:00:00 EST","open":7.36,"high":7.52,"low":7.145,"amount":18498335.3262703,"amplitude":0.050403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.0624602,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":7.44,"preHourTrading":{"tag":"盘前","latestPrice":7.4,"preClose":7.44,"latestTime":"09:28 EST","volume":5317,"amount":39526.620536,"timestamp":1769178487843,"change":-0.04,"changeRate":-0.005376,"amplitude":0.017473},"postHourTrading":{"tag":"盘后","latestPrice":7.28,"preClose":7.27,"latestTime":"19:10 EST","volume":40257,"amount":292698.8893,"timestamp":1769213432636,"change":0.01,"changeRate":0.001376,"amplitude":0.008102},"volumeRatio":0.8943392944806323,"impliedVol":0.6622,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/CRMD/tweets","defaultTab":"tweets","newsList":[{"id":"2606257620","title":"Is CorMedix (CRMD) A Potential Opportunity After Recent Share Price Volatility?","url":"https://stock-news.laohu8.com/highlight/detail?id=2606257620","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606257620?lang=en_us&edition=fundamental","pubTime":"2026-01-25 19:27","pubTimestamp":1769340434,"startTime":"0","endTime":"0","summary":"If you are wondering whether CorMedix at around US$7.27 is priced as a bargain or a trap, you are not alone. That is exactly what this valuation focused rundown aims to unpack.\nThe stock has been volatile recently, with a 7.2% gain over the last 7 days, a 42.0% decline over 30 days, and year to date and 1 year returns of 40.2% and 41.5% declines. The 3 year return sits at 68.7% and the 5 year return at a 16.9% decline.\nRecent trading moves have put CorMedix back on the radar for investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/is-cormedix-crmd-a-potential-opportunity-after-recent-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/is-cormedix-crmd-a-potential-opportunity-after-recent-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRMD","BK4007","DCF"],"gpt_icon":0},{"id":"2605758472","title":"CorMedix Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605758472","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605758472?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:08","pubTimestamp":1769170080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 07:08 ET (12:08 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2605712194","title":"CorMedix Inc : H.c. Wainwright Cuts Target Price to $13 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2605712194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605712194?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:13","pubTimestamp":1769166799,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO0PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2605474397","title":"CorMedix price target lowered to $13 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2605474397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605474397?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:10","pubTimestamp":1769166642,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on CorMedix (CRMD) to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2605476314","title":"CorMedix Inc. Director Janet Dillione Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605476314","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605476314?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:30","pubTimestamp":1769135442,"startTime":"0","endTime":"0","summary":"Janet Dillione, Director of CorMedix Inc., reported a disposal of common shares of CorMedix Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDLlpqXv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CorMedix Inc. Director Janet Dillione Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2605796105","title":"CorMedix Inc : RBC Cuts Target Price to $13 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2605796105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605796105?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:04","pubTimestamp":1768993491,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2603953622","title":"CorMedix Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Michael David Seckler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603953622","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603953622?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:25","pubTimestamp":1768530343,"startTime":"0","endTime":"0","summary":"CorMedix Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Michael David Seckler, who serves as Chief Commercial Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL6wT7pJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CorMedix Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Michael David Seckler","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2603633968","title":"CorMedix (CRMD) Valuation After New Leadership Moves And 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603633968","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603633968?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:16","pubTimestamp":1768302962,"startTime":"0","endTime":"0","summary":"Leadership moves and fresh guidance at CorMedix\nCorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$320 million, alongside appointing Mike Seckler as EVP & Chief Commercial Officer.\nSee our latest analysis for CorMedix.\nThe leadership changes and fresh 2026 revenue guidance arrive after a sharp pullback in CorMedix’s share price. The 7 day share price return shows a decline of 36.50% and the year to date...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/cormedix-crmd-valuation-after-new-leadership-moves-and-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRMD"],"gpt_icon":0},{"id":"2603085579","title":"Analysts Conflicted on These Healthcare Names: Cormedix (CRMD), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603085579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603085579?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:20","pubTimestamp":1768274412,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), BioMarin Pharma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMRN","BK4581","XBI","BK4139","BK4007","LABU","LU0029874061.USD","BK4137","LU2065171402.SGD","IE0002270589.USD","ACAD","BK4585","LU2065170008.USD","LU2065171311.SGD","HCSG","CRMD","IE00B19Z3581.USD","LU0128526141.USD","XLV","IE00B7SZLL34.SGD","BK4588","BK4566","IE00B19Z3B42.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"1134045879","title":"Stock Track | CorMedix Inc. Plummets 5.24% Intraday After Leerink Partners Slashes Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1134045879","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134045879?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228577,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) saw its stock plummet by 5.24% during intraday trading on Monday, following a significant target price cut by Leerink Partners.The investment firm reduced its target price for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2602512187","title":"CorMedix Inc : Leerink Partners Cuts Target Price to $15 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512187?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:28","pubTimestamp":1768220885,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"1143784563","title":"Stock Track | CorMedix Inc. Soars 5.46% Intraday as CEO Prepares for J.P. Morgan Healthcare Conference Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1143784563","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143784563?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:32","pubTimestamp":1767969140,"startTime":"0","endTime":"0","summary":"CorMedix Inc. (CRMD) saw its stock price surge by 5.46% during Friday's intraday session, reflecting strong investor optimism.The rally appears to be driven by the announcement that CorMedix's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CRMD"],"gpt_icon":0},{"id":"2602376096","title":"CorMedix CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376096?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965451,"startTime":"0","endTime":"0","summary":"CorMedix Inc. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30pm PST. Chairman and CEO Joseph Todisco is scheduled to deliver the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3l57TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","SG9999014013.SGD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4007","CRMD"],"gpt_icon":0},{"id":"2602339706","title":"CorMedix Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2602339706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602339706?lang=en_us&edition=fundamental","pubTime":"2026-01-09 03:57","pubTimestamp":1767902220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 14:57 ET (19:57 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2602397269","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602397269","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602397269?lang=en_us&edition=fundamental","pubTime":"2026-01-09 03:37","pubTimestamp":1767901029,"startTime":"0","endTime":"0","summary":"CorMedix  reported Q4 preliminary net revenue on Thursday, a touch below the average analyst estimate compiled by FactSet, and its forecast range for full-year 2026 sales also missed consensus.Shares of the health care firm sank 33% following an increase in intraday trading volume to over 19 million from a daily average of about 2.78 million.Acuity  shares sank 14% after the lighting and building management solutions provider left its full-year adjusted earnings and sales outlook unchanged, taking the shine off its fiscal Q1 adjusted earnings beat.More than 822,000 shares of the company traded intraday compared with a daily average of about 249,000.Genelux  said Thursday it priced an underwritten public offering of about 6.67 million shares at $3 each, targeting gross proceeds of roughly $20.0 million.Shares of the biopharmaceutical company slumped 18% as intraday trading volume soared to over 1.23 million from a daily average of about 237,000.Price: 7.54, Change: -3.63, Percent Change","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4096","AYI.AU","BK7062","LU0054578231.USD","LU0203345920.USD","AYI","BK4139","LU0203347892.USD","GNLX","CRMD","BK4007"],"gpt_icon":0},{"id":"2602394547","title":"CorMedix price target lowered to $16 from $20 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2602394547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602394547?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:45","pubTimestamp":1767894322,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on CorMedix (CRMD) to $16 from $20 and keeps a Buy rating on the shares after the company introduced a FY26 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-16-from-20-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-16-from-20-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2602399794","title":"CorMedix Slides on Preliminary FY25 Results, FY26 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602399794","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602399794?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:07","pubTimestamp":1767892020,"startTime":"0","endTime":"0","summary":"Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026.The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025.CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026.The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare & Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters.\"If CMS utilizes the same methodology to calculate\" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expe","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2601367835","title":"CorMedix Reports Q4 Preliminary Net Revenue, Provides Guidance; Names CEO Joseph Todisco Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601367835?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:43","pubTimestamp":1767879793,"startTime":"0","endTime":"0","summary":"CorMedix  reported Q4 preliminary net revenue Thursday of $127 million.Analysts surveyed by FactSet expected $128.3 million.The company said it expects 2026 revenue of $300 million to $320 million.Analysts surveyed by FactSet expect $435.7 million.CorMedix also named Chief Executive Joseph Todisco chairman of the board of directors, succeeding Myron Kaplan, who will become lead independent director, which is a new position on the board.Shares of CorMedix were down more than 8% pre-bell.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2601236216","title":"BRIEF-Cormedix Therapeutics Announces Preliminary Fourth Quarter And Full Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2601236216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601236216?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:33","pubTimestamp":1767879220,"startTime":"0","endTime":"0","summary":"BRIEF-Cormedix Therapeutics Announces Preliminary Fourth Quarter And Full Year 2025 Results Jan 8 (Reuters) - CorMedix Inc CRMD.O:CORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA9NTPXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2601647293","title":"GUIDANCE: (CRMD) CorMedix Expects 2026 Revenue Range $300M to $320M, vs. FactSet Est of $435.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2601647293","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601647293?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:18","pubTimestamp":1767878320,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRMD) CorMedix Expects 2026 Revenue Range $300M to $320M, vs. FactSet Est of $435.7","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":0.0723},{"period":"1month","weight":-0.4036},{"period":"3month","weight":-0.3491},{"period":"6month","weight":-0.3673},{"period":"1year","weight":-0.4089},{"period":"ytd","weight":-0.3749}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.13066},{"month":2,"riseRate":0.533333,"avgChangeRate":0.076401},{"month":3,"riseRate":0.533333,"avgChangeRate":0.047277},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.013888},{"month":5,"riseRate":0.2,"avgChangeRate":-0.123071},{"month":6,"riseRate":0.5625,"avgChangeRate":0.053114},{"month":7,"riseRate":0.4375,"avgChangeRate":0.055385},{"month":8,"riseRate":0.5625,"avgChangeRate":0.025363},{"month":9,"riseRate":0.375,"avgChangeRate":0.027376},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction